Drug
histamine dihydrochloride
histamine dihydrochloride is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Phase Distribution
Ph not_applicable
1
25%
Ph phase_2
1
25%
Ph phase_3
2
50%
Phase Distribution
0
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(1)
Other(2)
Detailed Status
unknown2
Completed1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (25.0%)
Phase 32 (50.0%)
N/A1 (25.0%)
Trials by Status
completed125%
unknown250%
active_not_recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
active_not_recruitingnot_applicable
Role of Interleukin-13 Pathways on Pain and Itch Sensitivity ( IL-13 )
NCT07017231
unknownphase_3
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver
NCT00039234
completedphase_3
Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia
NCT00003991
unknownphase_2
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Metastatic Kidney Cancer
NCT00005038
Clinical Trials (4)
Showing 4 of 4 trials
NCT07017231Not Applicable
Role of Interleukin-13 Pathways on Pain and Itch Sensitivity ( IL-13 )
NCT00039234Phase 3
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver
NCT00003991Phase 3
Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia
NCT00005038Phase 2
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Metastatic Kidney Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4